Moderna, Inc.
MRNA
Classement en actions
#238
Moderna, Inc., a biotechnology firm, is dedicated to the discovery,... Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Prix de l'action
$241.53
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$96.43B
Changement (1 jour)
6.45%
Changement (1 an)
778.61%
Pays
US
Échange Moderna, Inc. (MRNA)
Catégorie
Healthcare
Nombre d'actions en circulation pour Moderna, Inc. (MRNA)
Nombre d'actions en circulation au June 2026: 396.00M
Selon les derniers rapports financiers et le cours de l'action de Moderna, Inc., le nombre actuel d'actions en circulation est de 396.00M. À la fin de December 2024, l'entreprise avait 384.00M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Moderna, Inc. (MRNA) de 2016 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2026 (TTM) | 396.00M | 1.80% |
| 2025 | 389.00M | 1.30% |
| 2024 | 384.00M | 0.52% |
| 2023 | 382.00M | -3.05% |
| 2022 | 394.00M | -2.23% |
| 2021 | 403.00M | 5.68% |
| 2020 | 381.33M | 15.28% |
| 2019 | 330.80M | 0.61% |
| 2018 | 328.80M | -12.55% |
| 2017 | 376.00M | 486.64% |
| 2016 | 64.09M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| 253.90M | -35.88% |
US
|
|
| 478.91M | 20.94% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -84.30% |
NL
|
|
| 0.00 | -100.00% |
BE
|
